Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials

NEW YORK, NY--(Marketwired - May 7, 2014) - Nuvilex, Inc.'s (OTCQB: NVLX) advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA approved pancreatic cancer drug Gemzar^®, then it was NASDAQ's Celgene and its recently FDA approved treatment of Abraxane^® plus gemcitabine, and now the latest treatment that Nuvilex's Cell-in-a-Box^® combined with the anticancer drug ifosfamide outperforms is NASDAQ-listed Merrimack Pharmaceuticals and its treatment, the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin.

Between these three biopharmaceutical firms, each has FDA approval or is about to face the FDA seeking approval for an advanced pancreatic cancer treatment. They also represent 3 separate treatments that Nuvilex's Cell-in-a-Box^®/ifosfamide combination has produced better data than in two successfully completed Phase I/II clinical trials.

Merrimack Pharmaceuticals announced last week that its combination of MM-398 with 5-fluorouracil and leucovorin achieved an overall survival of 6.1 months in the company's Phase 3 clinical trials conducted in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy.

This announcement is great news for pancreatic cancer patients and the Pancreatic Cancer Action Network whose CEO Julie Fleshman said of the results, "The Pancreatic Cancer Action Network's goal is to double pancreatic cancer survival by 2020. The positive results of this trial demonstrate progress toward that goal in a disease for which additional treatment options are urgently needed to improve patient outcomes."

With these latest results, the stage is set for Nuvilex in the pancreatic cancer arena as they prepare to begin late phase clinical trials with a treatment that may just get the Pancreatic Cancer Action Network to its goal sooner than 2020. Results from previous clinical trials using Nuvilex's Cell-in-a-Box^®/ifosfamide treatment included a median survival time of 11 months versus 8.5 months for patients treated with a combination of Abraxane plus gemcitabine versus 6.7 months for gemcitabine alone. So, one thing is for sure Nuvilex can compete with big pharma, and in the end, it may top them all.

About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a platform for corporate stories to unfold in the media with Reports, Interviews and Articles. SMMG is compensated for Nuvilex articles, reports, and interviews by a third party who reserves the right to buy, sell or remain neutral on securities after the publication of this article. SMMG has received total compensation of $81,695 for content related to Nuvilex. Additionally, a principal at SMMG currently owns 200,000 total shares of Nuvilex issued by the company through a consulting agreement which has since ended for work unrelated to content development. The shares have been held for the requisite period under Rule 144 as of April 30, 2013, and are eligible to be sold immediately without further notice. For more information: www.stockmarketmediagroup.com.